Evidence map›Paper›PMID 34823407›Full record

ArticleInternational journal of immunopathology and pharmacology

Entecavir-associated thrombocytopenia.

Yi Yu, Hao Feng

Open access · goldAbstract readCase Reports
In one paragraph

Article in International journal of immunopathology and pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Yi YuInfectious Diseases Section, 91599Nanjing Jiangbei Hospital, Nanjing, China.ORCID https://orcid.org/0000-0002-2066-2496
Hao FengInfectious Diseases Section, 91599Nanjing Jiangbei Hospital, Nanjing, China.ORCID https://orcid.org/0000-0002-2066-2496
Nanjing Jiangning Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Entecavir (ETV) is widely used in the treatment of hepatitis B, but there are only a few reports about entecavir-associated thrombocytopenia, and it is considered as an immediate response and inappropriate to continue the treatment with other nucleoside analogues. Now, we report the third case, and this case was delayed response and we switched to treatment with tenofovir (TDF). There was a 66-year-old female who was infected with hepatitis B virus (HBV). Her platelet count decreased from 111*10

Indexed as

ThrombocytopeniaAgedAntiviral AgentsDrug MonitoringDrug SubstitutionFemaleGlucocorticoidsGuanineHepatitis BHumansPlatelet CountPlatelet TransfusionPrednisoneTenofovirTreatment OutcomeAntiviral AgentsentecavirGlucocorticoidsGuaninePrednisoneTenofovirentecavirentecavir-associated thrombocytopeniahepatitis Btenofovir

Identifiers

PMID34823407
PMCPMC8674478
OpenAlexW3217761077

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.